Publications

Jensen IS, Wu E, Cyr PL, Gauden D. Cost-consequence of use of Fluciclovine (F 18) for the diagnosis and staging of recurring prostate cancer. ISPOR 16th Annual European Congress, Glasgow, Scotland, 2017.

Jensen IS, Wu E, Sacks N, Cyr P, Chung K. 2017. Budget impact analysis of CPX-351 in the treatment of patients with treatment-related acute myeloid leukemia (tAML) or AML with myelodysplasia-related changes (MRC) from a US payer perspective. Blood 130(Sup 1):5615; 10.1182/blood.V130.Suppl_1.5615.5615.

Jensen I, Zacherle E, Blanchette C, Zhang J, Yin W. 2016. Evaluating cost benefits of combination therapies for advanced melanoma. Drugs Context 5:212297; doi: 10.7573/dic.212297.

Jensen IS, Wu C, Fan W, Lodise T, Nicolau, DP, DuFour S, Cyr PL, et al. 2016. Use of oritivancin in moderate-severe ABSSSI patients requiring IV antibiotics: US hospital budget impact analysis. J Manag Care Spec Pharm 22(6):752-64; doi: 10.18553/jmcp.2016.22.6.752.

Jensen IS, Lodise TP, Fan W, Wu C, Cyr PL, Nicolau DP, DuFour S, et al. 2016. Use of oritavancin in acute bacterial skin and skin structure infection patients receiving intravenous antibiotics: A US hospital budget impact analysis. Clin Drug Investig. 2016 36(2):157-68; doi: 10.1007/s40261-015-0365-8.

Wu E, Jensen IS, Cyr PL, Fan W, Mitchell M, Sulham K, Nathwani D. Use of oritavancin for the treatment of skin and soft tissue infections: A UK hospital budget impact analysis. ISPOR 20th Annual International Meeting, Philadelphia, PA, 2015.

Jensen I, Halbert R, Giuseppe R, Naoshy S, Iqbal SU, Zhimin X, McSweeney P. 2015. A hospital budget impact model to evaluate plerixafor in stem cell mobilization: Impact of primary research and direct stakeholder engagement. Eur J Hosp Pharm 22(3):142–149; doi: 10.1136/ejhpharm-2014-000543.

Wu C, Fortier KJ, LaPensee K, Fan W, Mitchell M, Cyr PL, Jensen IS. A US hospital economic impact model for oritavancin in ABSSSI patients with risk of MRSA infections. Abstract PSS10. ISPOR 17th Annual European Congress 2014.

Jensen IS, Bay C, Cyr PL. Estimating the impact of combining cangrelor and bivalirudin to a U.S. hospital performing PCI procedures. ISPOR 18^th Annual International Meeting, New Montreal Quebec, 2014.

Jensen IS, Wu C, Bay CB, Cyr PL. Estimating the clinical value of cangrelor in patients undergoing PCI. International Academy of Cardiology, 19th World Congress on Heart Disease, Boston, MA, 2014.

Wu C, Fortier K, Fan WJ, LePensse K, Bay CB, Cyr PL, Jensen IS. A U.S. hospital budget impact model for oritivancin in ABSSSI patients with risk of MRSA infections. ISPOR 16^th Annual European Congress, Amsterdam, Netherlands, 2014.

Bay C, Cyr PL, Jensen IS. Estimating the value of cangrelor from eliminating preloading in coronary artery bypass graft (CABG) patients. ISPOR 16th Annual European Congress, Amsterdam, Netherlands, 2014.

Casale RA, Jensen IS, Egholm M. 1999. Synthesis of PNA oligomers by Fmoc chemistry. In Peptide Nucleic Acids: Protocols & Applications. Weymondham, UK: Horizon Scientific Press.

Casale RA, Paul CH, Jensen IS, Moyer ML, Kates SA, Egholm M. 1998. A comparison of solid supports for PNA synthesis. In Epton R (ed), Innovation and Perspectives in Solid Phase Synthesis and Combinatorial Libraries. Birmingham, England: Mayflower Worldwide Limited.